Monthly Triple-Drug Combo Lowers Immune Reactions in Leprosy
A study found that monthly rifampin-moxifloxacin-minocycline (RMM) therapy reduces the risk of type 1 immunologic reactions in leprosy patients compared to traditional multidrug therapy (MDT). The research involved 111 patients treated at a Miami clinic, revealing a significant difference in type 1 reaction rates between the two therapies. While RMM therapy showed promise, the authors noted the need for further studies to confirm its effectiveness due to limitations in sample size and study design.
- ▪Monthly RMM therapy was associated with a lower risk for type 1 immunologic reactions than MDT in leprosy patients.
- ▪Type 1 reactions occurred in 56% of patients receiving MDT, while RMM therapy significantly reduced this risk.
- ▪The study was conducted with 111 patients at a Miami HD clinic between October 2010 and November 2025.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Monthly rifampin-moxifloxacin-minocycline (RMM) therapy was associated with a lower risk for type 1 immunologic reactions than multidrug therapy (MDT) in patients with leprosy (Hansen disease [HD]) in a study.METHODOLOGY:Researchers conducted a retrospective cohort study of 111 patients with biopsy- and polymerase chain reaction-confirmed HD treated at a Miami HD clinic between October 2010 and November 2025.The mean age of the patients was 52 years (range, 15-85 years); 62% were male; 40%-43% were Hispanic, 52%-56% were non-Hispanic, 9%-12% were Black or African American, and 84%-88% were White; 70% had multibacillary disease.Patients received either World Health Organization-recommended MDT (monthly rifampin and daily dapsone and clofazimine; n = 86, 77%), the global gold…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
